TBX-2400
/ Taiga Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 10, 2021
Taiga Initiates Phase 1/2 Clinical Study of TBX-2400 in Acute Myeloid Leukemia and Myelofibrosis in Croatia
(PRNewswire)
- "Taiga Biotechnologies...announced today that the Company has completed the site initiation session for the first site to participate in the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT), in Croatia."
Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Myelofibrosis • Oncology
October 11, 2021
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
(clinicaltrials.gov)
- P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.; Initiation date: Jun 2021 ➔ Dec 2021
Clinical • Trial initiation date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation • PTPRC
May 07, 2021
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
(clinicaltrials.gov)
- P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.; Initiation date: Mar 2021 ➔ Jun 2021
Clinical • Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation • PTPRC
January 14, 2021
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
(clinicaltrials.gov)
- P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.
Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation
1 to 4
Of
4
Go to page
1